BidaskClub upgraded shares of NeoGenomics (NASDAQ:NEO) from a sell rating to a hold rating in a report released on Monday.
Several other brokerages have also recently issued reports on NEO. Scotiabank set a $22.00 price objective on NeoGenomics and gave the stock an outperform rating in a report on Wednesday, January 3rd. Janney Montgomery Scott reaffirmed a buy rating on shares of NeoGenomics in a report on Thursday, October 26th. Zacks Investment Research raised NeoGenomics from a sell rating to a hold rating in a research report on Friday, October 20th. CIBC set a $19.00 price target on NeoGenomics and gave the stock a neutral rating in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada set a $23.00 price target on NeoGenomics and gave the stock an outperform rating in a research report on Wednesday, January 3rd. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $15.83.
NeoGenomics (NASDAQ:NEO) opened at $7.23 on Monday. The stock has a market capitalization of $602.27, a price-to-earnings ratio of 149.80, a P/E/G ratio of 3.02 and a beta of 0.57. NeoGenomics has a 1-year low of $7.08 and a 1-year high of $11.63. The company has a current ratio of 2.14, a quick ratio of 1.99 and a debt-to-equity ratio of 0.57.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.